|
Adverum Biotechnologies, Inc. (ADVM) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Adverum Biotechnologies, Inc. (ADVM) Bundle
Ingementada para su precisión, nuestra calculadora ADVM DCF le permite evaluar la valoración de Adverum Biotechnologies, Inc. utilizando datos financieros del mundo real, ofreciendo flexibilidad completa para modificar todos los parámetros esenciales para proyecciones mejoradas.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .3 | .0 | 7.5 | .0 | 3.6 | 1.8 | .9 | .5 | .2 | .1 |
| Revenue Growth, % | 0 | -100 | 0 | -100 | 0 | -50 | -50 | -50 | -50 | -50 |
| EBITDA | -62.9 | -112.2 | -140.9 | -147.9 | -112.6 | -.4 | -.2 | -.1 | .0 | .0 |
| EBITDA, % | -25165.2 | 100 | -1878.6 | 100 | -3127.75 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | 1.6 | 4.2 | 4.6 | 6.5 | 5.6 | 1.7 | .8 | .4 | .2 | .1 |
| Depreciation, % | 629.2 | 100 | 61.93 | 100 | 156.78 | 92.39 | 92.39 | 92.39 | 92.39 | 92.39 |
| EBIT | -64.5 | -116.4 | -145.5 | -154.5 | -118.2 | -.4 | -.2 | -.1 | .0 | .0 |
| EBIT, % | -25794.4 | 100 | -1940.53 | 100 | -3284.53 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 166.0 | 429.7 | 305.2 | 185.6 | 96.5 | 1.8 | .9 | .5 | .2 | .1 |
| Total Cash, percent | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | 5.7 | .0 | .0 | 1.0 | .5 | .2 | .1 | .1 |
| Account Receivables, % | 0 | 100 | 76.12 | 100 | 0 | 55.22 | 55.22 | 55.22 | 55.22 | 55.22 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .7 | .4 | .2 | .1 | .0 |
| Inventories, % | 0 | 100 | 0 | 100 | 0 | 40 | 40 | 40 | 40 | 40 |
| Accounts Payable | 4.1 | 2.8 | 1.4 | 2.2 | 1.9 | 1.3 | .7 | .3 | .2 | .1 |
| Accounts Payable, % | 1641.2 | 100 | 18.49 | 100 | 53.36 | 74.37 | 74.37 | 74.37 | 74.37 | 74.37 |
| Capital Expenditure | -19.2 | -11.8 | -15.1 | -11.8 | -.8 | -.8 | -.4 | -.2 | -.1 | -.1 |
| Capital Expenditure, % | -7698.8 | 100 | -201.64 | 100 | -22.44 | -44.49 | -44.49 | -44.49 | -44.49 | -44.49 |
| Tax Rate, % | 0.91168 | 0.91168 | 0.91168 | 0.91168 | 0.91168 | 0.91168 | 0.91168 | 0.91168 | 0.91168 | 0.91168 |
| EBITAT | -64.5 | -117.5 | -145.5 | -154.5 | -117.2 | -.4 | -.2 | -.1 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -78.1 | -126.5 | -163.2 | -153.3 | -112.6 | -1.8 | .4 | .2 | .1 | .1 |
| WACC, % | 6.32 | 6.32 | 6.32 | 6.32 | 6.29 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 1 | |||||||||
| Present Terminal Value | 1 | |||||||||
| Enterprise Value | 0 | |||||||||
| Net Debt | 0 | |||||||||
| Equity Value | 0 | |||||||||
| Diluted Shares Outstanding, MM | 10 | |||||||||
| Equity Value Per Share | -0.01 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Adverum Biotechnologies, Inc. (ADVM) financial data pre-filled to facilitate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A refined Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, validating strategies, and enhancing efficiency.
Key Features
- Comprehensive Financial Data: Access precise pre-loaded historical information and future forecasts for Adverum Biotechnologies, Inc. (ADVM).
- Tailorable Projection Inputs: Modify highlighted fields such as WACC, growth rates, and profit margins to suit your analysis.
- Real-Time Calculations: Automatic adjustments for DCF, Net Present Value (NPV), and cash flow evaluations.
- Interactive Dashboard: User-friendly charts and summaries to help visualize your valuation findings.
- Designed for All Users: An intuitive layout crafted for investors, financial officers, and consultants alike.
How It Works
- Download: Obtain the pre-built Excel file containing Adverum Biotechnologies, Inc.'s (ADVM) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC as needed.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various forecasts and analyze results immediately.
- Make Decisions: Leverage the valuation insights to inform your investment strategy.
Why Choose Adverum Biotechnologies, Inc. (ADVM) Calculator?
- All-in-One Solution: Combines DCF, WACC, and financial ratio analyses tailored for biotechnology.
- Flexible Inputs: Modify highlighted fields to explore different investment scenarios.
- In-Depth Analysis: Automatically computes Adverum’s intrinsic value and Net Present Value.
- Data-Rich Environment: Access to historical and projected data for reliable analysis.
- Expert-Level Tool: Perfect for biotech analysts, investors, and strategic consultants.
Who Should Use This Product?
- Biotech Investors: Develop comprehensive and accurate valuation models for analyzing ADVM stock.
- Corporate Strategy Teams: Evaluate valuation scenarios to inform strategic decisions within the company.
- Financial Consultants: Deliver precise valuation insights to clients interested in Adverum Biotechnologies, Inc. (ADVM).
- Students and Instructors: Utilize real-world biotech data to enhance learning in financial modeling courses.
- Healthcare Sector Enthusiasts: Gain insights into how biotech firms like Adverum are valued in the stock market.
What the Adverum Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations for Adverum Biotechnologies, Inc. (ADVM).
- Real-World Data: Adverum's historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to Adverum.
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results tailored to Adverum Biotechnologies, Inc. (ADVM).